83例睾丸间质细胞瘤患者的临床表现、管理与随访:一项前瞻性病例队列研究
该前瞻性病例队列研究纳入2009至2018年10年间诊断的83例睾丸间质细胞瘤(LCT)患者,与90例精原细胞瘤患者及2683例无睾丸病变者比较。LCT与男性不育、隐睾和男性乳房发育相关,患者即使肿瘤切除后仍存在内分泌和生精异常风险,需长期随访。在依从性好的患者中,主动监测似乎是手术剜除的安全替代方案。
要点
- LCT与男性不育、隐睾和男性乳房发育强烈相关。
- LCT患者即使肿瘤切除后仍有内分泌和生精异常风险,需长期随访。
- 在依从性好的患者中,主动监测似乎是手术剜除的安全替代方案。
核心结论
- LCT比通常认为的更常见,与男性不育、隐睾和男性乳房发育相关,在依从性好的患者中应保守治疗并采用主动监测,这似乎是手术剜除的安全替代方案。
- LCT早期识别时肿瘤学预后良好,保留组织的剜除术可治愈并应取代睾丸切除术。
- 保守手术以及在依从性好的患者中通过临床和影像学随访进行的主动监测是安全选择,但需要监测睾丸功能衰竭和复发。
研究设计与样本
- 前瞻性病例队列研究,2009年至2018年10年间连续纳入诊断的LCT患者,并与同期筛查的精原细胞瘤或无睾丸病变的匹配队列比较。
- 共纳入83例LCT患者、90例精原细胞瘤患者和2683例无睾丸病变者。
- 入组者接受病史和临床检查,并接受常规血液检查、激素检查(FSH、LH、总睾酮、雌二醇、抑制素B、性激素结合球蛋白(SHBG)、催乳素)和精液分析。
- 同意者还接受超声造影、弹性成像、钆增强阴囊磁共振成像和hCG刺激试验(5000 IU肌内注射),在0、24、48和72小时测量血清总睾酮和雌二醇。
主要发现
- LCT通过剜除术(48.2%)、睾丸切除术(13.3%)或临床监测(38.5%)诊断。
- LCT组睾丸体积、精子浓度和形态均低于无睾丸病变组(分别为P=0.001、P=0.001和P<0.001)。
- LCT组FSH、LH和SHBG高于无睾丸病变组,睾酮/LH比值低于无睾丸病变组(P<0.001)。
- LCT组SHBG高于精原细胞瘤组(P=0.018),精子浓度低于精原细胞瘤组(P=0.029),活力低于精原细胞瘤组(P=0.049)。
- LCT的危险因素为隐睾(χ2=28.27,P<0.001)、男性乳房发育(χ2=54.22,P<0.001)和睾丸体积低(χ2=11.13,P=0.001);5例为复发或双侧病变,随访期间(中位66个月)无转移发生。
关键数值与推荐
- LCT与男性不育、隐睾和男性乳房发育强烈相关,支持睾丸发育不良综合征在其发生中起作用的假说。
- LCT患者即使肿瘤切除后仍有较高的内分泌和生精异常风险,因此需要长期随访并在诊断后及时努力保留生育功能。
- LCT早期识别时肿瘤学预后良好,保留组织的剜除术可治愈并应取代睾丸切除术。
- 保守手术以及在依从性好的患者中通过临床和影像学随访进行的主动监测是安全选择,但需要监测睾丸功能衰竭和复发。
临床怎么用
- 在依从性好的患者中,主动监测似乎是手术剜除的安全替代方案。
- 保留组织的剜除术可治愈并应取代睾丸切除术。
- 保守手术和主动监测需要监测睾丸功能衰竭和复发。
局限性
- hCG和第二线诊断检查并非所有肿瘤患者都可获得。
- 本研究所在中心为不育转诊中心,选择偏倚可能改变了LCT人群的基线特征;但比较队列也来自同一中心并采用类似方案管理,作者不预期有显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: When should 'not so rare' Leydig cell tumors (LCTs) of the testis be suspected, diagnosed, and treated? SUMMARY ANSWER: LCTs are more frequent than generally believed, are associated with male infertility, cryptorchidism and gynecomastia, and should be treated conservatively (in compliant patients) with active surveillance, which appears to be a safe alternative to surgical enucleation. WHAT IS KNOWN ALREADY: Increasing referrals for testicular imaging have led to an increase in findings of LCTs. The features and natural history of these tumors remain largely unknown, as the available studies are small and heterogeneous. LCTs were previously treated aggressively and follow-up data are lacking. STUDY DESIGN, SIZE, DURATION: A case-cohort study of consecutive patients diagnosed with LCTs over a 10-year period was prospectively enrolled from 2009 to 2018 and compared to matched cohorts of patients with seminomas or no testicular lesions screened in the same timeframe. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 9949 inpatients and outpatients referred for scrotal ultrasound, a total of 83 men with LCTs were included. Enrolled subjects underwent medical history and clinical examination and were asked to undergo routine blood tests, hormone investigations (FSH, LH, total testosterone, estradiol, inhibin B, sex hormone-binding globulin (SHBG), prolactin), and semen analysis. Patients who consented also underwent contrast-enhanced ultrasound, elastography, gadolinium-enhanced scrotal magnetic resonance imaging, and hCG stimulation test (5000 IU i.m.) with serum total testosterone and estradiol measured at 0, 24, 48, and 72 hours. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 83 patients diagnosed with LCTs were compared against 90 patients diagnosed with seminoma and 2683 patients without testicular lesions (NoL). LCTs were diagnosed by enucleation (48.2%), orchiectomy (13.3%), or clinical surveillance (38.5%). Testicular volume, sperm concentration, and morphology were lower (P = 0.001, P = 0.001, and P < 0.001, respectively) in patients with LCTs than in the NoL group. FSH, LH, and SHBG were higher and the testosterone/LH ratio was lower in LCTs than in the NoL group (P < 0.001). The LCT group showed higher SHBG (P = 0.018), lower sperm concentration (P = 0.029), and lower motility (P = 0.049) than the seminoma group. Risk factors for LCTs were cryptorchidism (χ2 = 28.27, P < 0.001), gynecomastia (χ2 = 54.22, P < 0.001), and low testicular volume (χ2 = 11.13, P = 0.001). Five cases were recurrences or bilateral lesions; none developed metastases during follow-up (median, 66 months). LIMITATIONS, REASONS FOR CAUTION: This study has some limitations. First, hCG and second-line diagnostic investigations were not available for all tumor patients. Second, ours is a referral center for infertility, thus a selection bias may have altered the baseline features of the LCT population. However, given that the comparison cohorts were also from the same center and had been managed with a similar protocol, we do not expect a significant effect. WIDER IMPLICATIONS OF THE FINDINGS: LCTs are strongly associated with male infertility, cryptorchidism, and gynecomastia, supporting the hypothesis that testicular dysgenesis syndrome plays a role in their development. Patients with LCTs are at a greater risk of endocrine and spermatogenesis abnormalities even when the tumor is resected, and thus require long-term follow-up and prompt efforts to preserve fertility after diagnosis.LCTs have a good oncological prognosis when recognized early, as tissue-sparing enucleation is curative and should replace orchiectomy. Conservative surgery and, in compliant patients, active surveillance through clinical and radiological follow-up are safe options, but require monitoring of testicular failure and recurrence. STUDY FUNDING/COMPETING INTEREST(S): The project was funded by the Ministry of University and Research Grant MIUR 2015ZTT5KB. There are no conflicts of interest. TRIAL REGISTRATION NUMBER: ALCeP trial (ClinicalTrials.gov Identifier: NCT01206270).
引用
- Pozza C, Pofi R, Tenuta M, et al. Clinical presentation, management and follow-up of 83 patients with Leydig cell tumors of the testis: a prospective case-cohort study. Hum Reprod. 2019. PMID: 31532522. doi:10.1093/humrep/dez083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。